Contineum Therapeutics (CTNM) Stock Price, News & Analysis

Company Overview

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $9.83 to $10.67
• 50-Day Range: $3.65 to $10.04
• 52-Week Range: $3.35 to $20.55
• Volume: 214,010 shs
• Average Volume: 206,175 shs
• Market Capitalization: $278.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.75
• Consensus Rating: Buy

Contineum Therapeutics Stock Analysis - MarketRank™

Contineum Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 338th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Contineum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Contineum Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Contineum Therapeutics are expected to grow in the coming year, from ($2.01) to ($1.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Contineum Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Contineum Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Contineum Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.97% of the float of Contineum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Contineum Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Contineum Therapeutics has recently decreased by 39.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Contineum Therapeutics does not currently pay a dividend.

Dividend Growth

Contineum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.97% of the float of Contineum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Contineum Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Contineum Therapeutics has recently decreased by 39.40%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.60

News Sentiment

Contineum Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Contineum Therapeutics this week, compared to 1 article on an average week.

Search Interest

4 people have searched for CTNM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Contineum Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.30% of the stock of Contineum Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

CTNM Stock Analysis - Frequently Asked Questions

How have CTNM shares performed this year?

Contineum Therapeutics' stock was trading at $14.65 on January 1st, 2025. Since then, CTNM shares have decreased by 32.2% and is now trading at $9.94.

How were Contineum Therapeutics' earnings last quarter?

Contineum Therapeutics, Inc. (NASDAQ:CTNM) announced its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.06.

When did Contineum Therapeutics IPO?

Contineum Therapeutics (CTNM) raised $110 million in an initial public offering on Friday, April 5th 2024. The company issued 6,875,000 shares at a price of $16.00 per share.

Who are Contineum Therapeutics' major shareholders?

Top institutional shareholders of Contineum Therapeutics include Franklin Resources Inc. (6.57%), Perceptive Advisors LLC (2.70%), Versant Venture Management LLC (2.10%) and Saturn V Capital Management LP (1.23%).

How do I buy shares of Contineum Therapeutics?

Shares of CTNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Contineum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Contineum Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTNM
• Previous Symbol: NASDAQ:CTNM
• CIK: 1855175
• Web: www.contineum-tx.com
• Phone: (858) 333-5280
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Contineum Therapeutics: $22.75
• High Price Target: $31.00
• Low Price Target: $16.00
• Potential Upside/Downside: +128.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.75%
• Return on Assets: -28.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.51
• Quick Ratio: 24.51

Sales & Book Value

• Annual Sales: $50 million
• Price / Sales: 5.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.11 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 28,040,000
• Free Float: 24,873,000
• Market Cap: $278.72 million
• Optionable: N/A
• Beta: 1.04